Evidence map›Paper›PMID 37388736›Full record

ArticleFrontiers in immunology2023

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China.

Jingyun Tang, Humin Liu, Qing Wang, Xiaobo Gu, Jia Wang, Wenjun Li, Yinglan Luo, Yan Li, Lan Deng, Yue Luo and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Jingyun TangBlood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China.
Humin LiuDepartment of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China.
Qing WangDepartment of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China.
Xiaobo GuDepartment of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China.
Jia WangDepartment of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China.
Wenjun LiDepartment of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China.
Yinglan LuoDepartment of Blood Testing, Chengdu Blood Center, Chengdu, Sichuan, China.
Yan LiDepartment of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China.
Lan DengDepartment of Blood Collection, Chengdu Blood Center, Chengdu, Sichuan, China.
Yue LuoBlood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China.
Xinman DuBlood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China.
Donglin TanDepartment of Blood Processing, Chengdu Blood Center, Chengdu, Sichuan, China.
Xuemei FuBlood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China.
Xue ChenBlood Research Laboratory, Chengdu Blood Center, Chengdu, Sichuan, China.
Guangzhou Blood Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Demographic information has been shown to help predict high antibody titers of COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the Chinese population and little evidence on whole-blood donors. Therefore, we aimed to investigate these associations among Chinese blood donors after SARS-CoV-2 infection. Methods: In this cross-sectional study, 5,064 qualified blood donors with confirmed or suspected SARS-CoV-2 infection completed a self-reported questionnaire and underwent tests of SARS-CoV-2 Immunoglobulin G (IgG) antibody and ABO blood type. Logistic regression models were used to calculate odds ratios (ORs) for high SARS-CoV-2 IgG titers according to each factor. Results: Totally, 1,799 participants (with SARS-CoV-2 IgG titers≥1:160) had high-titer CCPs. Multivariable analysis showed that a 10-year increment in age and earlier donation were associated with higher odds of high-titer CCP, while medical personnel was associated with lower odds. The ORs (95% CIs) of high-titer CCP were 1.17 (1.10-1.23, p< 0.001) and 1.41 (1.25-1.58, p< 0.001) for each 10-year increment in age and earlier donation, respectively. The OR of high-titer CCP was 0.75 (0.60-0.95, p = 0.02) for medical personnel. Female early donors were associated with increased odds of high-titer CCP, but this association was insignificant for later donors. Donating after 8 weeks from the onset was associated with decreased odds of having high-titer CCP compared to donating within 8 weeks from the onset, and the HR was 0.38 (95% CI: 0.22-0.64, p <0.001). There was no significant association between ABO blood type or race and the odds of high-titer CCP. Discussion: Older age, earlier donation, female early donors, and non-medical-related occupations are promising predictors of high-titer CCP in Chinese blood donors. Our findings highlight the importance of CCP screening at the early stage of the pandemic.

Indexed as

Blood Group AntigensCOVID-19Antibodies, ViralBlood DonorsChinaCOVID-19 SerotherapyCross-Sectional StudiesFemaleHumansImmunoglobulin GSARS-CoV-2Antibodies, ViralBlood Group AntigensImmunoglobulin GChineseconvalescent plasma screeningCOVID-19cross-sectional studySARS-CoV-2 IgG titerwhole-blood donors

Identifiers

PMID37388736
PMCPMC10303911
OpenAlexW4380611798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.